Y-Biologics (XKRX:338840) ROCE % : -3.58% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Y-Biologics's annualized ROCE % for the quarter that ended in Sep. 2024 was -3.58%.

Y-Biologics ROCE % Historical Data

The historical data trend for Y-Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics ROCE % Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-66.71

-39.28

-49.86

-82.82

-109.34

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial						-37.10	-344.08	-26.41	-61.53	-3.58

Y-Biologics ROCE % Calculation

Y-Biologics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-20727.289	/	( ( (29322.649 - 16195.42)	+	(30294.014 - 5507.822) )	/ 2 )
	=	-20727.289	/	( (13127.229	+	24786.192)	/ 2 )
	=	-20727.289	/	18956.7105
	=	-109.34 %

Y-Biologics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-755.068	/	( ( (24111.828 - 2839.483)	+	(24520.195 - 3582.791) )	/ 2 )
	=	-755.068	/	( ( 21272.345	+	20937.404 )	/ 2 )
	=	-755.068	/	21104.8745
	=	-3.58 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Y-Biologics (XKRX:338840) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Y-Biologics ROCE % Related Terms

Thank you for viewing the detailed overview of Y-Biologics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

B715 Daedeok Biz Center, 17 Techno 4-ro, Yuseong-gu, Daejeon, KOR, 34013

Website

https://www.ybiologics.com

Y-Biologics Inc is a company that has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of the development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics Headlines

No Headlines